X
<

A Look at Pfizer's Key Drivers in 2017

PART:
1 2 3 4 5 6 7 8 9 10 11 12 13 14
A Look at Pfizer's Key Drivers in 2017 PART 1 OF 14

How Did Pfizer Perform in 3Q17?

Pfizer’s revenue trends

In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis. In 3Q17 and the first nine months of 2017, Pfizer reported net income of $2.8 billion and $9.0 billion, respectively, compared to $1.4 billion and $6.4 billion in the corresponding periods of 2016.

In 3Q17, Pfizer reported diluted earnings per share (or EPS) of $0.47 compared to $0.22 in 3Q16. Pfizer reported YTD September 2017 diluted EPS of $1.49 compared to $1.04 in YTD September 2016. In 3Q17, Pfizer reported adjusted income and adjusted diluted EPS of $4.1 billion and $0.67, respectively, compared to $3.7 billion and $0.61 in 3Q16. Pfizer reported YTD September 2017 adjusted income and adjusted diluted EPS of $12.3 billion and $2.03, respectively, compared to $11.9 billion and $1.92 in YTD September 2016.

How Did Pfizer Perform in 3Q17?

Interested in IVV? Don't miss the next report.

Receive e-mail alerts for new research on IVV

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Pfizer’s expenses

In 3Q17, Pfizer reported the cost of sales of $2.8 billion compared to $3.1 billion in 3Q16. In 3Q17, Pfizer reported SI&A (selling, informational, and administrative) and R&D (research and development) expenses of $3.5 billion and $1.9 billion, respectively, compared to $3.6 billion and $1.9 billion in 3Q16.

Pfizer reported YTD September 2017 cost of sales, SI&A, and R&D expenses of $8.0 billion, $10.2 billion, and $5.3 billion, respectively, compared to around $9.1 billion, $10.4 billion, and $5.4 billion in YTD September 2016.

Peers Johnson & Johnson (JNJ), Merck (MRK), and Novartis (NVS) reported revenues of $19.7 billion, $10.3 billion, and $12.4 billion, respectively. The revenue growth of Pfizer could boost the iShares Core S&P 500 ETF (IVV). Johnson & Johnson and Pfizer make up about ~1.7% and ~0.95% of IVV’s total portfolio holding, respectively.

X

Please select a profession that best describes you: